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To the Editor: Tsai and Lian [1] and Furlan et al [2]
Reply from the Authorindependently demonstrated that a deficiency in the activ-
Deficiency of von Willebrand factor-cleaving proteaseity of von Willebrand factor-cleaving metalloprotease,
(ADAMTS-13) activity should not be considered the soleADAMTS-13 or the presence of its inhibitory antibodies
criterion for administering plasma therapy to patients withcauses thrombotic thrombocytopenic purpura. It is un-
thrombotic microangiopathies (TMA). Actually most pa-known whether a similar mechanism occurs in patients
tients with different forms of TMA, including geneticwho develop thrombotic microangiopathy (TMA) follow-
forms associated with factor H deficiency, referred to theing organ transplantation. We have recently shown that
Italian Registry for Recurrent and Familial hemolytic ure-the ADAMTS-13 activity was undetectable in plasma
mic syndrome (HUS) and thrombotic thrombocytopenicsamples obtained from a patient who developed TMA
purpura (TTP) responded to plasma therapy [1], regard-after receiving a cadaveric renal allograft. Deficiency of
less of ADAMTS-13 activity. Thus, restricting plasma in-the protease enzyme occurred in the presence of its inhibi-
fusion or exchange to cases with congenital or acquiredtory antibodies. Discontinuation of cyclosporine and daily
deficiency of ADAMTS-13 activity would deprive someplasma exchange raised the ADAMTS-13 activity, fol-
TMA patients of the only potentially effective treatment.
lowed by resolution of the microangiopathic hemolysis
Moreover, assays of ADAMTS-13 activity are lengthy
and improvement of the graft function [3]. and available only in specialized reference laboratories.
Ruggeneti [4] pointed out in an article recently pub- Thus, plasma therapy should be decided on the basis of
lished in Kidney International that restoration of von clinicopathologic observations [2]. Samples for later de-
Willebrand factor-cleaving protease activity in parallel termination of ADAMTS-13 activity could be collected
with disease remission does not necessarily imply that before plasma therapy is started. The activity level may
normalization of the protease activity is the determinant influence subsequent therapeutic decisions [3]. Sporadic
of response to plasma. We are curious if this is based forms, including posttransplant TMA, are often precipi-
on case studies or solely speculations. In our case, we tated by drugs. In these forms, drug discontinuation and
showed that the ADAMTS-13 activity rapidly increased plasma exchange usually rise ADAMTS-13 activity and
to 50% or higher after two sessions of plasmapheresis. remove the inhibitors. In recurrent forms with congenital
We further showed that the immunoglobulin G (IgG) ADAMTS-13 deficiency, plasma induces disease remis-
molecules isolated from the patient’s plasma inhibited sion even before, or without, normalizing ADAMTS-13
the ADAMTS-13 activity in normal plasma. During activity [4]. In forms with continuous formation of the
disease remission, the IgG molecules isolated from the inhibitor, we and others have seen that the antibody titer
patient’s plasma showed no inhibitory effect on the decreases immediately after treatment, but returns to
ADAMTS-13 activity in normal plasma. We speculate pretreatment values shortly after stopping plasma, after
in cases that do not recur [4].that plasma exchange confers its effectiveness by replen-
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Lagaaij et al [3] have recently reported that graftsA prospective trial correlating clinical outcomes with
in which the endothelial cells are damaged by vascularADAMTS-13 activity levels will clarify the role of re-
rejection may incorporate host endothelium as part ofplenishing ADAMTS-13 and/or removing inhibitors in
the repair process. They speculate that host endothelialdeterming TMA response to plasma therapy.
cells may be recruited from endothelial stem cells in the
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Endothelial chimerism in
Risk factors for late kidneyassociation with vascular
allograft failurerejection in patients after
To the Editor: We congratulate Ponticelli et al [1] forkidney transplantation an excellent paper regarding the evaluation of risk fac-
tors for late kidney allograft failure that recently ap-
peared in Kidney International. However, we would like
To the Editor: Cell migration from the host to the to suggest to the authors to see for the effect of nephron
transplanted organ results in chimerism in the organ [1]. dosing on late allograft failure. Although the authors
Chimerism may be detected after gender-mismatched have evaluated body mass index (BMI) (25 vs. 25)
organ transplantation with use of fluorescence in situ as a risk factor and found no significant effect. This may
hybridization [2]. To verify the endothelial chimerism, not have become significant as extreme BMI groups were
we studied kidney grafts with immunohistochemistry for not considered separately. Meier-Kriesche et al have
ABO blood-group antigens and in situ hybridization for observed in their study that the relative risk of graft loss
Y chromosome. death censored and uncensored was more in extremes
Four male recipients had received living kidney trans- of BMI compared to other categories. It was evident
that of the extreme groups the relative risk of chronicplants from female donors. The blood type of the recipi-
allograft nephropathy (CAN) was significantly more inents was type A in all cases, and that of donors were
high BMI group [2]. We have observed in our study andtype O in two cases and type B in two cases. Needle
it has been well reported by others that kidneys withbiopsies were performed from 2 to 5 months after kidney
insufficient nephron mass for the recipient may be dam-transplantation and diagnosed as vascular rejection. En-
aged by hyperfiltration injury resulting into proteinuriadothelial cells stained with CD34 were positive for Y
and CAN [3–5]. Thus we feel that if authors can analyzechromosomes, indicating the presence of recipient-type
nephron dosing in addition to other well studied riskmale cells. These endothelial cells were positively stained
factors in this cohort, it would be a significant contribu-for recipient-type blood group A. The patients in the
tion to the literature.
present study have shown that replacement of donor
endothelium by recipient cells does occur in vascular Navalkishor Udgiri, Randeep Kashyap, and Mukut Minz
Chandigarh, Indiarejection after kidney transplantation.
